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Abstract
Introduction: The ectodomain shedding of epider-
mal growth factor receptor (EGFR) ligands, such
as amphiregulin (AREG), by ADAMs (A Disintegrin
And Metalloproteases) can be stimulated by G
protein-coupled receptor (GPCR) agonists. Inter-
actions between the CXCR4 GPCR and the
CXCL12 chemokine have been shown to mediate
gene transcription and cellular proliferation in non-
transformed and transformed prostate epithelial
cells, as well as motility ⁄ invasiveness in transformed
cells.
Objectives: In this report, we investigated the ability
of CXCL12 to stimulate amphiregulin ectodomain
shedding in non-transformed and transformed pros-
tate epithelial cells that respond proliferatively to
sub-nanomolar levels of CXCL12 and amphiregulin.
Materials and Methods: Non-transformed N15C6
and transformed PC3 prostate epithelial cells
were assessed for amphiregulin shedding, ADAM
activation, Src phosphorylation and EGFR activa-
tion using ELISA, immunoblot, and immunopreci-
pitation techniques, and for proliferation using
cell counting after stimulation with CXCL12 or
vehicle.
Results: The results of these studies identify
CXCL12 as a novel inducer of amphiregulin ecto-
domain shedding and show that both basal and
CXCL12-mediated amphiregulin shedding are
ADAM10- and Src kinase-dependent in non-trans-
formed N15C6 cells. In contrast, amphiregulin shed-
ding is not amplified subsequent to stimulation with
exogenous CXCL12, and is not reduced subsequent
to metalloprotease- or Src kinase-inhibition, in
highly aggressive PC3 prostate cancer cells. These
data also show that CXCL12-mediated cellular pro-
liferation requires EGFR transactivation in a Src-
and ADAM-dependent manner in non-transformed
prostate epithelial cells. However, these same
mechanisms are dysfunctional in highly transformed
prostate cancer cells, which secrete amphiregulin in
an autocrine manner that cannot be repressed through
metalloprotease- or Src kinase inhibition.
Conclusion: These findings show that non-trans-
formed and transformed prostate epithelial cells may
employ different mechanisms to activate EGFR
ligands and thereby utilize the EGFR axis to promote
cellular proliferation.
Introduction
Chemokines are soluble, low molecular weight
(8–14 kDa) chemotactic cytokines that bind to their cog-
nate G-protein coupled receptors (GPCRs) to elicit cell
responses (1). They govern multiple aspects of host
defence and inflammation such as haematopoiesis, leuko-
cyte trafficking and angiogenesis (2). However, beside
their classical role as leukocyte chemoattractants, chemo-
kines have been shown to play important roles in tumour
biology, specially with regard to angiogenesis, motility,
cell invasiveness, and cell proliferation (3,4).
CXCL12, also known as stromal cell-derived factor-1
(SDF-1), is a CXC-type chemokine that is constitutively
expressed in a wide variety of tissues and binds to the
seven-transmembrane GPCR, CXCR4. The CXCL12 ⁄
CXCR4 axis is involved in angiogenesis, migration and
invasiveness of cancer cells, and tumour-cell proliferation
(reviewed by 5). Recently, our laboratory studies have
shown that the CXCL12 ⁄CXCR4 axis mediates cell pro-
liferation in both non-transformed and transformed pros-
tate epithelial cells (6,7). Several cellular mechanisms
could account for the observed CXCL12-mediated
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proliferative response. For example, CXCL12 ⁄CXCR4
interactions may activate molecular pathways known to
stimulate cell proliferation. It has been shown by us and
others that CXCL12 ⁄CXCR4 interactions can stimulate
signalling through pro-proliferative Raf ⁄MEK ⁄ERK as
well as PI3K ⁄PTEN ⁄Akt pathways, although the
CXCL12-mediated proliferative response has been
observed to be ERK-dependent in non-transformed pros-
tate epithelial cells and ERK-independent in transformed
prostate epithelial cells (7–9). These studies suggest that
common CXCL12-mediated proliferative and transcrip-
tional responses observed for prostate epithelial cells may,
in fact, be governed by multiple signalling pathways.
A further mechanism that may account for the
observed CXCL12-stimulated proliferative response is
that CXCL12 ⁄CXCR4 interactions may transactivate
other membrane-bound receptors, which then stimulate
signalling pathways involved in cell proliferation. Several
studies have shown that GPCRs (such as chemokine
receptors, for example CXCR4) can cross-activate other
receptors, including epidermal growth factor receptor
(EGFR). Such cross-activation is thought to occur through
a Gbc-mediated mechanism (10–13). Activated EGFR,
in turn, can activate (primarily) the Raf ⁄MEK ⁄ERK,
PI3K ⁄PTEN ⁄Akt and JAK ⁄STAT pathways, and thereby
promote cell proliferation (14–17).
A third type of mechanism that may account for
CXCL12-mediated cell proliferation is upregulation
and ⁄or activation of growth-factor type ligands (cyto-
kines, EGF-type ligands, and more) that promote cell pro-
liferation. GPCRs, like CXCR4, are known to activate
Src, PKC and reactive oxygen species, which serve as sec-
ond messengers of activated G-proteins and can catalyse
activation of membrane-bound sheddases termed ADAMs
(14,18,19). In particular, interactions between the
CXC-type chemokine, IL-8, and GPCRs that recognize
it, CXCR1 and CXCR2 have been shown to stimulate
shedding of EGFR ligands, heparin-binding epidermal
growth factor (HB-EGF) and amphiregulin, in gastric
cancer cells, in an ADAM10-dependent manner (20).
The study reported here raises the possibility that
chemokines may stimulate shedding of potent, mitogenic
EGF-type ligands, that this process may be mediated by
ADAMs, and that EGF-type ligand ⁄ receptor interac-
tions may contribute to the observed CXCL12 ⁄CXCR4-
mediated proliferative response. To test this hypothesis,
we examined whether CXCL12 ⁄CXCR4 interactions
may mediate shedding of EGF-type ligands in non-
transformed or transformed human prostate epithelial
cells, whether this process is Src- and ADAM-dependent,
and whether consequent EGFR transactivation contrib-




N15C6 and N1 cells were produced through immortal-
ization of primary human prostate epithelial or stromal
fibroblast cultures, respectively, by transduction with a
recombinant retrovirus encoding the E6 and E7 genes of
HPV-16, as described previously (21). Both N15C6 and
N1 cells are non-transformed and grow continuously in
culture, but do not form colonies in soft agar nor tumours
in immunocompromised mice (22,23). N15C6 and N1
cells were maintained in 5% HIE media (Ham’s F12;
Mediatech Inc., Herndon, VI, USA) with 5% foetal
bovine serum (Invitrogen, Carlsbad, CA), 5 lg ⁄ml insulin,
10 ng ⁄ml EGF and 1 lg ⁄ml hydrocortisone (Sigma Chem-
ical Co., St Louis, MO, USA), or in defined serum-free HI
(SF) media supplemented with 5 mM ethanolamine (Sigma
Aldrich), 10 mM HEPES (Sigma Aldrich), 5 lg ⁄ll trans-
ferrin (Sigma Aldrich), 10 lM 3,3¢,5-triiodo-L-thyronine
(Sigma Alrdich), 50 lM sodium selenite (Sigma Aldrich),
0.1% bovine serum albumin (BSA; JRH Biosciences,
Lenexa, KS, USA), 0.05 mg ⁄ml gentamicin (Invitrogen,
Carlsbad, CA) and 0.5 lg ⁄ml fungizone (Cambrex Bio-
science, Walkersville, MD, USA). Benign prostatic hyper-
plasia-1 (BPH-1) cells are SV40 Large T-immortalized,
non-transformed prostate epithelial cells and were main-
tained in 10% RPMI media (24). Androgen-sensitive
LNCaP and 22Rv1, and androgen-insensitive PC3 and
DU145 transformed prostate epithelial cell lines were
maintained in 10% RPMI media or SF RPMI (without
phenol red) and antibiotics as described above (25–28).
For amphiregulin shedding assays, N1 and N15C6 cells
were maintained in SF HI media with 0.05% BSA, and
BPH-1, LNCaP, 22Rv1, PC3 and DU145 cell lines were
maintained in phenol red-free SF RPMI with 0.05% BSA.
Quantitative real-time PCR
All quantitative real-time assays were conducted as previ-
ously described using an Applied Biosystems 7900HT
instrument and reagents (6,7). Cells were grown to 70%
confluence in 60 mm dishes prior to RNA purification
using Trizol reagent (Invitrogen, Carlsbad, CA). For all
experiments, 1 lg of RNA was reverse transcribed using
Superscript III reverse transcriptase (Invitrogen). Result-
ing cDNA was diluted to the ratio of 1:100. Real-time
PCR was performed using Assays on Demand (Applied
Biosystems, Foster City, CA, USA) according to the man-
ufacturer’s instructions. Reactions within individual
experiments were performed in triplicate, including no
template controls and an endogenous control probe,
RPLPO (ribosomal protein, large, PO), to assess template
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concentration. Cycle numbers to threshold were calculated
by subtracting averaged control from averaged experimen-
tal values, and fold gene expression was calculated by
raising these values to log 2. 6-carboxy-fluorescine-conju-
gated, gene-specific assays were Hs00155832_m1 for
AREG and Hs99999902_m1 for the control, RPLPO.
Amphiregulin shedding assays
To assess basal levels of amphiregulin shedding, 300 000
cells each were plated in six-well plates in complete
medium (5% HIEC for N1 and N15C6 and 10% RPMI for
BPH-1, LNCaP, 22Rv1, PC3 and DU145) which was
changed to SF HI for N1 or N15C6 cells, or to SF RPMI
for BPH-1, LNCaP, 22Rv1, PC3, or DU145 cells for 24 h
prior to assessment of basal amphiregulin shedding, which
was determined by ELISA (R&D Systems, Minneapolis,
MN) and normalized to pg ⁄ml ⁄million cells. Effects of
exogenous CXCL12 on amphiregulin shedding were
determined by treating serum-deprived cells with vehicle
(0.1% BSA in phosphate-buffered solution (PBS)) and
10 pM CXCL12 for N15C6 cells or 100 pM CXCL12 for
PC3 cells or 10 pM and 100 pM for both LNCaP and
22Rv1 cells, for 60 min, followed by replacement with
fresh serum-free medium for 4 h. Conditioned medium
was then harvested, concentrated and tested by ELISA to
quantify amphiregulin (R&D Systems #262-AR-100,
#MAB262, #BAF262). Effects of pan-metalloprotease
inhibitors, O-phenanthroline (OPT), galardin (GM 6001),
and tumour necrosis factor-a inhibitor-1 (TAPI-1),
ADAM10-specific inhibitor, INCB008765 (29), Src fam-
ily kinase inhibitor 4-amino-5-(4-methylphenyl)-7-
(t-butyl)pyrazolo(3,4-d)-pyrimidine (PP1) and its
negative control 4-amino-7-phenylpyrazol[3,4-d] pyrimi-
dine, PP3, on CXCL12-stimulated amphiregulin shed-
ding, were examined by treating serum-deprived cells
with 500 lM OPT (Sigma), 5 lM GM6001 (Calbiochem,
San Diego, CA), 2 lM TAPI-1 (Calbiochem), 5 or 10 lM
INCB008765, 5 or 10 lM of PP1 (Invitrogen, Carlsbad,
CA), 10 lM of PP3 (Calbiochem) or vehicle (0.1% metha-
nol for OPT, 0.05% dimethyl sulphoxide (DMSO) for
GM6001, TAPI-1, and PP3, 0.025% or 0.05% DMSO for
INCB008765 and PP1, for 1 h, followed by treatment
with 10 pM CXCL12 for N15C6 cells or 100 pM CXCL12
for PC3 cells. The conditioned medium was then har-
vested, concentrated and tested using ELISA to quantify
amphiregulin presence, which was normalized as
pg ⁄ml ⁄million cells.
Immunoblotting and protein analysis
Cells were lysed, proteins resolved by electrophoresis
and electroblotting was carried out as described previ-
ously (6,7). Proteins were detected using antibodies
against ADAM10 (Millipore, Billerica, MA, #AB19026),
ADAM17 (R&D Systems, #AB930), phospho-Src Y418
(Invitrogen #44-660G), pan-Src family protein (Cell Sig-
naling, Danvers, MA, #2110), pan anti-phosphotyrosine,
clone 4G10 (Millipore, Billerica, MA, NY, USA), phos-
pho-EGFR Y992 (Cell Signaling, #2235), EGFR (Cell
Signaling, #2232), tubulin (Millipore, Billerica, MA,
#DM1A) or actin (Santa Cruz, #sc-1615) in conjunction
with an ECL detection system. Secondary antibodies
including goat anti-rabbit (Cell Signaling, #7074), goat
anti-mouse (Santa Cruz, CA, #SC-2005), and mouse
anti-goat (Santa Cruz, #A3105) were used at 1:5000
concentration. Immunoblots shown are representative of
replicate experiments. Densitometric quantification of
immunoblot films was accomplished by scanning origi-
nal films and converting .tiff files to greyscale. Images
were inverted and mean band intensities were measured
using IMAGEJ (http://rsbweb.nih.gov/ij/index.html). Mean
intensity of adjacent background was also measured
for each band and subtracted from band intensity. Densi-
tometric data were averaged from replicate experi-
ments (as indicated in the figures) and standard
deviations were calculated for graphical depiction and
statistical analysis.
Immunoprecipitation assay and ELISA for Src activity
The effect of Src family kinase inhibitor, PP1, and its neg-
ative control, PP3, on CXCL12-stimulated Src family pro-
tein activity in N15C6 cells, was examined by treating
serum-deprived cells with vehicle (0.025% or 0.05%
DMSO), 5 or 10 lM of PP1 (Biosource), 10 lM of PP3 for
1 h, followed by treatment with vehicle (0.1% BSA in
PBS), or 10 pM CXCL12. Cell lysates were evaluated
using ELISA for Src family protein phosphorylation at
tyrosine residue Y418, as described by the manufacturer
(Upstate, #14-468), with pSrcY418 quantified as units ⁄ml
medium ⁄ lg total protein (U ⁄ml ⁄lg). For immunoprecipi-
tation assays, cells were lysed in an RIPA buffer as
described previously (6,7). Cell lysates were centrifuged
at 14 000 g for 10 min at 4 C, and 200 lg of total pro-
tein were exposed to 1:330 dilution of anti-Src family pro-
tein antibody overnight at 4 C. Immunoprecipitates were
immobilized using protein-G-sepharose beads for 2 h at
4 C and were washed three times in the same buffer. Pre-
cipitated proteins were eluted in 40 ll of 2x Laemmli
sample buffer, boiled for 5 min and separated using 8%
SDS–PAGE. Immunoblots were subjected to densitomet-
ric analysis as described previously and these data were
averaged from replicate experiments (as indicated in the
figures); standard deviations were calculated for graphical
depiction and statistical analysis.
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Proliferation assays
Cell proliferation was assessed in triplicate in 24-well
plates and cells counted after 24 and 96 h incubation as
described previously (6,7). To assess the effects of exoge-
nous amphiregulin on cell proliferation, recombinant
human amphiregulin (R&D Systems, #262-AR-100) was
added at the desired concentration in 0.5 ml SF medium
(or 0.5 ml SF media alone for control) to each well. To
assess the effect of ADAM 10 specific inhibitor
INCB008765, MEK1 inhibitor U0126, and EGFR inhibi-
tor AG1478 (Tyrophostin) on cell proliferation, the cells
were pre-treated with vehicle (DMSO, 0.025% for
INCB8765 and 0.01% for U0126 and AG1478) or 5 lM
INCB008765, 1 lM U0126, 250 nM AG1478, followed
by supplementing medium with 10 ng ⁄ml EGF, 10 pM
CXCL12, or 100 pM amphiregulin. Cells were re-fed at
24 h growth and were counted at 24 and 96 h. Average
cell numbers and standard deviations were calculated over
three separate experiments for graphical depiction and
statistical analysis.
Statistical analysis
Data from replicate experiments (as indicated in the
figures) per study were averaged and standard deviations
were calculated for graphical depiction and statistical
analysis. Data were assessed using the t-test or analysis
of variance, with P < 0.05 considered statistically
significant.
Results
Autocrine secretion of amphiregulin by prostate epithelial
cells
To begin the study on whether CXCL12 might activate
EGF-type ligands to promote cell proliferation, we first
established basal levels of EGF-type ligand secretion in
non-transformed N1 prostate fibroblast cells, non-trans-
formed N15C6 and BPH-1 prostate epithelial cells, and
transformed LNCaP, 22Rv1, PC3 and DU145 prostate
epithelial cell lines. Using sandwich ELISA of serum-free
media conditioned by these cells for 24 h, we detected
levels of amphiregulin to be between 100 and
1000 pg ⁄ml ⁄million cells for five – N1, N15C6, BPH-1,
PC3 and DU145 – out of the seven cell lines tested. In
contrast, only very low levels of amphiregulin protein
shed into the media were detected for 22Rv1
(<10 pg ⁄ml ⁄million cells) or LNCaP (<1 pg ⁄ml ⁄million
cells) cells (Fig. 1a). These results are consistent with
those reported previously by Torring et al. (30), which




Figure 1. Profile of amphiregulin shedding, proliferative responses
and gene transcription in prostate epithelial cells. (a) Basal protein
levels (pg ⁄ml ⁄million cells) of amphiregulin (AREG) secreted after 12 h
growth in serum-free media by N1 prostate stromal fibroblast or N15C6,
BPH-1, 22Rv1, LNCaP, PC3 or DU145 prostate epithelial cells were
determined using ELISA and shown plotted on a logarithmic axis
(y-axis). Error bars reflecting deviations from the mean are plotted, but
are not evident as they comprise <1% error over replicate measures. (b)
Total cell number achieved by N15C6 (diamonds), LNCaP (squares) or
PC3 (triangles) cells after 96 h growth in serum-free (SF) media supple-
mented with 1, 10 or 100 pM or 1 nM AREG, or complete media with
serum (SERUM) normalized to growth in SF media alone is shown..
Both N15C6 and LNCaP cells proliferated in response to high concentra-
tions of CXCL12 to levels comparable with those achieved in complete
media with serum. In contrast, PC3 cells did not proliferate in response
to amphiregulin. Error bars reflect deviations from the mean for replicate
measures. (c) PC3, N15C6, 22Rv1 and LNCaP prostate epithelial cells
were treated with 1, 10 or 100 pM CXCL12 (as shown) and assessed for
transcription of the AREG gene using quantitative reverse-transcriptase
polymerase chain reaction (qRT-PCR) at 0, 10, 30 and 60 min treatment.
Transcript levels are normalized to those of an endogenous control tran-
script, RPLPO and are shown as fold amphiregulin transcript to levels
detected at time 0 (normalized to 1-fold). Error bars reflect deviations
from the mean for replicate experiments.
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protein was increased 10- to 100-fold in androgen-insensi-
tive PC3 compared to androgen-sensitive LNCaP cells.
Detection of presence of EGF-type ligands using ELISA,
for transforming growth factor (TGF)-alpha, HB-EGF and
EGF shed into the media by the seven cell lines, showed
only very low levels (<1 pg ⁄ml ⁄million cells) of these
proteins (not shown).
Amphiregulin-stimulated prostate epithelial cell prolifera-
tive response
To understand whether basal levels of amphiregulin
detected in the previous experiments might be sufficient to
induce proliferative responses in prostate epithelial cells,
representative cell lines – non-transformed N15C6 cells,
androgen-sensitive transformed LNCaP cells and andro-
gen-insensitive transformed PC3 cells – were grown in
serum-free media supplemented with escalating doses of
amphiregulin. As seen in Fig. 1b, N15C6 cells exhibited a
robust proliferative response to amphiregulin over a con-
centration range of 10 pM (100 pg ⁄ml) to 1 nM
(10 ng ⁄ml). The observation reported in this study was
that N15C6 cells secrete 100 pg ⁄ml ⁄million cells of
amphiregulin under basal conditions. Figure 1a suggests
that these cells may respond proliferatively to basal, as well
as higher, levels of amphiregulin. PC3 cells proliferated
modestly in response to exogenously administered amphi-
regulin over a concentration range of 10–100 pM (100–
1000 pg ⁄ml) (Fig. 1b). This concentration range included
that observed under conditions of basal secretion by PC3
cells (170 pg ⁄ml ⁄million cells). LNCaP cells responded
proliferatively to exogenous administration of amphiregu-
lin in the 100 pM (1 ng ⁄ml) to 1 nM (10 ng ⁄ml) range,
well above the low (<10 pg ⁄ml) level of amphiregulin
secreted by these cells under basal conditions. Therefore,
unlike N15C6 or PC3 cells, LNCaP cells failed to secrete
endogenously sufficient levels of amphiregulin under basal
conditions, to induce cell proliferation.
CXCL12 does not stimulate amphiregulin gene expression
It has been shown previously by our team that low, picomo-
lar levels of CXCL12 stimulate both proliferative and robust
and complex transcriptional responses in both non-trans-
formed N15C6 and transformed LNCaP prostate epithelial
cells (7). As other CXC-type chemokines, notably IL-8, had
been shown to stimulate shedding of EGF-type ligands (20),
it was examined whether shedding of amphiregulin (EGF-
type ligand most commonly detected in media of the cell
lines tested), might be stimulated in response to treatment
with concentrations of CXCL12 shown to promote prolifera-
tive responses in these cells. The first set of experiments
examined whether stimulation with exogenous CXCL12
might be associated with transcriptional activation of the
amphiregulin gene. As shown in Fig. 1c, none of the four
cell lines tested – non-transformed N15C6 cells, androgen-
sensitive transformed LNCaP or 22Rv1 cells, or androgen-
insensitive transformed PC3 cells – demonstrated significant
transcription of the amphiregulin gene in response to concen-
trations of CXCL12 associated with cell proliferation (1 or
10 pM CXCL12 for N15C6 cells, or 10 or 100 pM CXCL12
for PC3, LNCaP or 22Rv1 cells). These data suggested that
increased levels of amphiregulin expression as a result of
transcriptional activation of the amphiregulin gene were not
part of the mechanism involved in CXCL12-mediated prolif-
erative responses.
CXCL12 stimulated amphiregulin shedding in N15C6, but
not PC3, prostate epithelial cells
GPCR ⁄ ligand interactions, including those involving
CXC-type chemokine receptors and ligands, can stimulate
proteolytic processing and functional activation of EGFR
ligands (14,18–20). Therefore, we examined whether
CXCL12 could stimulate shedding of amphiregulin in
prostate epithelial cell lines. As shown in Fig. 2a, neither
LNCaP nor 22Rv1 cells shed amphiregulin into the media
in response to treatment with 10 or 100 pM CXCL12.
However, N15C6 cells treated with 10 pM CXCL12 dem-
onstrated approximately 1.3· higher levels of shed amphi-
regulin than untreated cells. This concentration of
CXCL12 has been shown to promote the proliferation of
N15C6 cells (6,7). In contrast, PC3 cells did not shed addi-
tional amphiregulin in response to treatment with 50 pM
CXCL12 (Fig. 2b) or 100 pM CXCL12 (not shown).
CXCL12 stimulates ADAM activation in N15C6, but not
PC3, cells
The preceding studies showed that CXCL12 did not stim-
ulate amphiregulin gene expression (Fig. 1c), but did
stimulate shedding of the ectodomain of amphiregulin
(Fig. 2b) in N15C6 cells. As recently reviewed by Ohtsu
et al. (19), ectodomains of EGF-type ligands, including
amphiregulin, EGF, epiregulin, HB-EGF and TGF-alpha,
are shed through activities of multiple ADAM-type prote-
ases, including ADAM9, 10, 12, 15, 17 and 19. Amphi-
regulin shedding is dependent on ADAM17 activation in
mouse embryonic cells (31), whereas chemokine-medi-
ated amphiregulin shedding is dependent on ADAM10
activation (19,20). Thus, next we examined whether
CXCL12 ⁄CXCR4 interactions could stimulate activation
of ADAM 10 and ⁄or ADAM17 and whether this mecha-
nism was associated with amphiregulin ectodomain shed-
ding and the observed cell proliferative response. These
experiments focused on CXCL12-mediated ADAM acti-
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vation in N15C6 and PC3 cells, as both these cell lines
exhibit high basal levels of shed amphiregulin (Fig. 1a),
but only N15C6 demonstrated additional amphiregulin
shedding upon treatment with CXCL12 (Fig. 2b).
ADAM proteins can exist as pro-form zymogens that
do not exert sheddase activities until they themselves are
proteolytically cleaved and activated (29,32). Cleavage of
the pro-forms of ADAM10 (100 kDa) and ADAM17
(120 kDa) and appearance of the active forms of these
proteins (at 60 and 80 kDa, respectively) may be observed
through immunoblot analysis. Immunoblot analysis of
protein lysates prepared from N15C6 cells grown in SF
HI media supplemented with 10 pM CXCL12 for 0, 10, 30
or 60 min demonstrated a 2.5-fold increase in the ratio of
active:pro-form ADAM10. Accumulation of pro-form
ADAM10 remained unchanged subsequent to CXCL12
stimulation. In contrast, N15C6 cells did not demonstrate
accumulation of pro- or active forms of ADAM17
(Fig. 3a,b). These data showed that CXCL12 selectively
stimulated ADAM10 activation in N15C6 cells. Similar
experiments conducted with PC3 cells grown in SF RPMI
media supplemented with 100 pM CXCL12 for 0, 10, 30
or 60 min did not demonstrate either activation or accu-
mulation of the pro-forms of ADAM10 or ADAM17 in
these cells (Fig. 3c,d). Low-level constitutive activation
of both ADAM10 and ADAM17 was also evident for
both N15C6 and PC3 cells grown in serum-free media
lacking EGF-ligands. Taken together, these data show that
CXCL12 stimulates rapid and robust activation of
ADAM10, but not ADAM17, in N15C6 cells.
CXCL12-stimulated amphiregulin shedding is metallopro-
tease-dependent
The previous experiments suggested that CXCL12 stimu-
lated amphiregulin shedding and robust ADAM10 activa-
tion in N15C6 cells, but not PC3 cells. However, as
recently reviewed by Sanderson et al. (33), ectodomain
shedding and activation of EGF-type ligands may be med-
iated through the activities of any of a family of matrix
metalloproteases (MMPs). MMPs comprise an enzyme
family that requires a zinc ion at their active site for cata-
lytic activity and include ‘classical’ MMPs, membrane-
bound MMPs (MT-MMPs), ADAMs and ADAMTS (a
disintegrin and metalloprotease with thrombospondin
motif). To determine whether metalloprotease activity
consistent with MMP family activation was required for
CXCL12-stimulated amphiregulin shedding, N15C6 cells
were treated with 10 pM CXCL12 in the presence of pan-
metalloprotease inhibitor, OPT, or solvent vehicle, 0.1%
methanol. The results of these experiments confirmed
accumulation of active 60 kDa form of ADAM10 to lev-
els approximately 3-fold higher in N15C6 cells treated for
60 min with CXCL12 compared to untreated cells. More-
over, cells pre-treated with 0.5 mM OPT followed by
60 min treatment with 10 pM CXCL12 failed to accumu-
late 60 kDa active form of ADAM10 (Fig. 4a–c). The
results were paralleled in experiments examining amphi-
regulin shedding under the same conditions, which
showed that N15C6 cells pre-treated with the solvent
vehicle 0.1% methanol shed amphiregulin into the media
subsequent to treatment with CXCL12 for 60 min. In con-
trast, pre-treatment with OPT not only inhibited CXCL12-
mediated amphiregulin shedding, but reduced the level of
(a)
(b)
Figure 2. Amphiregulin ectodomain shedding in response to
CXCL12. (a) 22Rv1 or LNCaP cells were treated for 60 min with vehi-
cle (0.1% BSA in PBS), 10 pM CXCL12, or 100 pM CXCL12 as shown,
their media replaced with fresh serum-free media and the cells grown for
4 h. Media were collected, shed amphiregulin levels were determined
using ELISA, and then normalized to pg ⁄ml per million cells. Neither
22Rv1 nor LNCaP shed amphiregulin in response to CXCL12. Error bars
reflect deviations from the mean for replicate measures. (b) N15C6 or
PC3 were treated for 60 min with vehicle (0.1% BSA in PBS), 10 pM
CXCL12 (N15C6) or 100 pM CXCL12 (PC3) and processed as described
in (a). Amphiregulin secretion is indicated as fold protein secreted com-
pared with time 0 (which is normalized to 1-fold). N15C6, but not PC3,
demonstrated significant (P < 0.05, indicated by *) secretion of amphi-
regulin in response to CXCL12. Error bars reflect deviations from the
mean for replicate measures.
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amphiregulin shed into the media below basal levels
(Fig. 4e). The results of these experiments implied that
metalloprotease activity, particularly that of activated
ADAM10, was required, and likely mediated, CXCL12-
stimulated amphiregulin shedding by N15C6 cells.
Similar experiments conducted in PC3 cells showed
that accumulation of activated ADAM10 was similar in
cells pre-treated with either OPT or vehicle, then treated
with 100 pM CXCL12 (Fig. 4b,d). Moreover, accumula-
tion of shed amphiregulin remained unaffected in PC3
cells under the same conditions (Fig. 4f). The results were
consistent with those reported earlier that CXCL12 did
not stimulate amphiregulin shedding above basal levels
and did not appreciably activate ADAM10 in PC3 cells.
Moreover, inhibition of metalloprotease activity did not
repress either ADAM10 activation nor amphiregulin shed-
ding in these cells.
CXCL12-mediated cell proliferation and amphiregulin
shedding are ADAM10-dependent
The results reported in this study suggest that metallopro-
tease activity was required for CXCL12-mediated amphi-
regulin ectodomain shedding in N15C6 cells and that
this activity was associated with ADAM10 activation
(Fig. 3,4). To assess whether CXCL12-mediated
ADAM10 activation contributed to the observed
CXCL12-stimulated proliferative response, N15C6 cells
were grown for 96 h in serum-free media in the presence of
DMSO (vehicle), 5 lM INCB008765 + vehicle, 10 pM
CXCL12 + vehicle or 5 lM INCB008765 + 10 pM
CXCL12 + vehicle. INCB008765 selectively inhibits
activity of ADAM10 (IC50 = 97 lM), but not that of
ADAM9, ADAM17, ADAM33 or the MMPs 1, 2 3, 7, 9,
12, 14 and 15 and has been shown to inhibit ectodomain
shedding of multiple EGF-type ligands including amphi-
regulin (29). As shown in Fig. 5a, CXCL12-mediated
proliferative response observed for N15C6 cells was abro-
gated when the cells were grown in media supplemented
with the ADAM10-specific inhibitor, INCB008765.
Further studies were then pursued to determine whether
ADAM10 was also required for CXCL12-mediated
amphiregulin shedding. For these experiments, N15C6
cells were treated with 10 pM CXCL12 after pre-treatment
with the solvent vehicle 0.05% DMSO or with one of three
metalloprotease inhibitors: 10 lM INCB008765, 2 lM
TAPI-1 or 5 lM GM6001 (all dissolved in 0.05% DMSO).
The results here show that N15C6 cells pre-treated with
vehicle and stimulated with CXCL12 shed amphiregulin
into the media, consistent with previously acquired data.
(a) (b) 
(c) (d) 
Figure 3. CXCL12 stimulates ADAM activation in prostate cancer cells. (a) Immunoblot analysis of protein lysates prepared from N15C6 cells
grown in SF HI media supplemented with 10 pM CXCL12 for 0 or 60 min. The active and pro-forms of ADAM 10 migrated at molecular weights of
approximately a 60 kDa form and 100 kDa and for ADAM17 an 80 kDa form and 120 kDa respectively. (b) Densitometric analysis of replicate immu-
noblots similar to that shown in (a). ADAM activation is indicated as the ratio of active ⁄ pro-form normalized to 1-fold at time 0. Treatment with
CXCL12 increased the ratio of active:pro-form ADAM10 by 2.5-fold (P < 0.05, indicated by *). Error bars reflect deviations from the mean for replicate
measures. (c) Immunoblot analysis of protein lysates prepared from PC3 cells grown in SF RPMI media supplemented with 100 pM CXCL12 for 0 or
60 min did not demonstrate accumulation of either the pro- or active forms of ADAM10 or ADAM 17. (d) Densitometric analysis of replicate immuno-
blots similar to that shown in (c) demonstrated a lack of accumulation of either the pro- or active forms of ADAM10 or ADAM 17 in PC3 cells treated
with CXCL12. ADAM activation is indicated as the ratio of active ⁄ pro-form normalized to 1-fold at time 0. Error bars reflect deviations from the mean
for replicate measures.
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However, amphiregulin shedding in response to CXCL12
was abrogated in N15C6 cells pre-treated with the selective
ADAM10 inhibitor, INCB008765 (Fig. 5b). Interestingly,
pre-treatment with the ADAM- and MMP-inhibitor
TAPI-1, as well as the MMP inhibitor, GM6001, also pre-
vented CXCL12-mediated amphiregulin shedding. Taken
together, these experiments suggest that the CXCL12-
mediated proliferative response in N15C6 cells was
ADAM10-dependent. These studies also showed that
CXCL12-mediated ADAM10 activation was required for
amphiregulin shedding in these cells and suggested that
MMP activation may be a component of this mechanism.
Src activation is required for CXCL12-mediated ADAM10
activation and amphiregulin shedding
CXCR4, the primary receptor for CXCL12, is a GPCR.
GPCRs are known to activate Src, which, in turn, has been
shown to activate other membrane-bound molecules
through ADAM-dependent mechanisms. In particular,
GPCR-coupled mechanisms have been shown to activate
both ADAM10 and ADAM17 (19). To understand the
mechanism through which CXCL12 ⁄CXCR4 interactions
activate ADAM10, which, in turn, mediates amphiregulin




Figure 4. CXCL12-mediated ADAM activation and amphiregulin shedding are metalloprotease-dependent. (a, b) Immunoblot analysis demon-
strating that N15C6 cells (a) pre-treated with the solvent vehicle, 0.1% methanol, then treated with 10 pM CXCL12 rapidly activated ADAM10, which
was abrogated by pre-treatment with the pan-metalloprotease inhibitor, o-phenanthroline (OPT). In contrast, PC3 cells (b) pre-treated with the solvent
vehicle, 0.1% methanol, then treated with 10 pM CXCL12 did not demonstrate ADAM10 activation. Pre-treatment with OPT did not dampen basal
ADAM10 activation in these cells. (c, d) Densitometric analysis of replicate immunoblots similar to that shown in (a). and (b) N15C6 cells (c) treated
with CXCL12 for 60 min demonstrated significant (P < 0.05, *) accumulation of the active form of ADAM10 to levels approximately 3-fold higher
after pre-treatment with vehicle compared with OPT-treated cells. PC3 cells (d) treated with CXCL12 did not demonstrate differences in accumulation
of the active form of ADAM10 after pre-treatment with either vehicle or OPT. ADAM10 activation is indicated as the ratio of active ADAM10 ⁄ pro-form
ADAM10 normalized to 1-fold at time 0. ADAM. The graph plots data were averaged over replicate experiments as indicated. Error bars reflect devia-
tions from the mean for replicate measures. (e, f) N15C6 cells (e), but not PC3 cells (f) treated for 60 min with CXCL12 shed significantly (P < 0.05,
indicated by *) higher levels of amphiregulin after pre-treatment with vehicle (0.1% BSA in PBS) compared with OPT pre-treated cells. Moreover,
amphiregulin shedding was reduced to below basal levels in OPT pre-treated N15C6 cells (P < 0.05, indicated by #) but not in OPT pre-treated PC3
cells. Amphiregulin secretion is indicated as fold protein secreted compared with time 0 (which is normalized to 1-fold). The graphs plot data averaged
over replicate experiments as indicated. Error bars reflect deviations from the mean for replicate measures.
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ated activation of Src was examined. For these experi-
ments, N15C6 cells grown for 16 h in serum-free media
were pre-treated for 60 min with either vehicle (DMSO)
or vehicle + 10 lM of Src family tyrosine kinase inhibitor,
PP1, supplemented with 10 pM CXCL12 and grown for
an additional 10, 30 or 60 min. Analysis of Src and
ADAM10 activation by immunoblot analysis showed that
N15C6 cells demonstrate significant and concomitant
accumulation of both phosphorylated Src (pSrc Tyr418)
and 60 kDa active form of ADAM10, in response to
CXCL12 (Fig. 6a). However, pre-treatment with the Src
family kinase inhibitor, PP1, prevented both Src phosphor-
ylation and ADAM10 activation consequent to CXCL12
stimulation (Fig. 6a). Immunoprecipitation of Src protein
from similarly treated N15C6 cells also demonstrated Src
phosphorylation in response to CXCL12, which was abro-
gated by pre-treatment with PP1 (Fig. 6b,c). Notably, con-
stitutive phosphorylation of Src within the activation loop,
indicative of Src kinase catalytic activity (34,35), is almost
indetectable using conventional Western blotting in
N15C6 cells, but is clearly detectable and abundant in
PC3 cells (Fig. 6b). Using ELISA-based assay for measur-
ing CXCL12-mediated Src phosphorylation that quanti-
fied accumulation of pSrcY418, we showed that N15C6
cells significantly (P < 0.05) accumulated pSrc in
response to CXCL12 and that this response was prevented
by pre-treatment with Src family kinase inhibitor PP1, but
not by the inactive analogue PP3 (Fig. 6d). Together, these
assays demonstrate that N15C6 cells phosphorylate
Src-family kinases that activate ADAM10 in response to
CXCL12 and that these responses can be abrogated by Src
family kinase inhibitor, PP1.
CXCL12-treated N15C6 or PC3 cells were further
examined to determine whether CXCL12-mediated Src
activation was required for amphiregulin shedding.
N15C6 or PC3 cells were cultured for 16 hrs incubation
in serum-free media followed by pre-treatment with PP1
or vehicle for 60 min, then with CXCL12 for an addi-
tional 60 min. Sandwich ELISA assessment of condi-
tioned media harvested from the cells demonstrated
significant accumulation of amphiregulin in the media of
N15C6 cells in response to CXCL12, which was abro-
gated by pre-treatment with Src family kinase inhibitor,
PP1. Neither CXCL12 treatment nor PP1 pre-treatment
affected amphiregulin shedding by PC3 cells (Fig. 6e).
Moreover, pre-treatment of N15C6 cells with inactive
PP1 analogue, PP3, failed to diminish amphiregulin shed-
ding significantly in response to CXCL12 stimulation
(Fig. 6f).
Taken together, the data described above suggest a
mechanism whereby CXCL12 ⁄CXCR4 interactions acti-
vate Src, which subsequently activates ADAM10, which
mediates amphiregulin cleavage and shedding and pro-
motes a proliferative response in non-transformed N15C6
cells. Conversely, amphiregulin shedding, ADAM10 acti-
vation and Src phosphorylation occur constitutively
through mechanisms that are unresponsive to chemical
inhibitors in highly transformed PC3 cells.
(a) (b)
Figure 5. CXCL12-mediated amphiregulin shedding and cell proliferation are ADAM10-dependent. (a) N15C6 cells were grown for 96 h in
serum-free (SF) media either non-supplemented or supplemented with vehicle, vehicle + 10 pM CXCL12 or vehicle + 10 pM CXCL12 + 5 lM
INCB008765 (as shown). Cell proliferation is indicated as the ratio of the total cell number under each supplemented condition (numerator) to non-sup-
plemented cell population growth (SF, which is set = 1). CXCL12-treated cells proliferated to levels significantly above those achieved in either SF or
SF + Vehicle (P < 0.05, indicated by *) except when grown in media supplemented with the ADAM10-specific inhibitor, INCB008765. Graph plot data
are averaged over replicate experiments as indicated. Error bars reflect deviations from the mean for replicate measures. (b) N15C6 cells were pre-treated
with vehicle or vehicle + 10 lM INCB008765, 10 lM TAPI-1 or 1 lM GM6001 for 60 min, and then stimulated with 10 pM CXCL12 for 4 h. The
media were collected and shed amphiregulin levels were determined using ELISA. Amphiregulin secretion is indicated as the ratio of the protein
detected in media from cells supplemented with 10 pM CXCL12 to that from non-supplemented cells (which is normalized to 1-fold). N15C6 cells dem-
onstrated significant (P < 0.05, indicated by *) secretion of amphiregulin in response to CXCL12, but this response was significantly diminished
(P < 0.05, indicated by #) in cells pre-treated with INCB008765, TAPI-1 or GM6001. Error bars reflect deviations from the mean for replicate mea-
sures.
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CXCL12-mediated proliferative response requires EGFR
transactivation
The observations reported in the present study, that
CXCL12 ⁄CXCR4 interactions stimulate amphiregulin
shedding through a Src- and ADAM10-dependent mecha-
nism, has suggested that this mechanism might promote
transactivation of EGFR and that this transactivation
might in turn, mediate CXCL12 ⁄CXCR4-stimulated
proliferative responses. To investigate this, N15C6 cells
were monitored for phosphorylation of EGFR subsequent
to treatment with CXCL12. Treatment of these cells with
(a) (b) (c) 
(d) (e) (f) 
Figure 6. CXCL12-mediated amphiregulin shedding is Src-dependent. (a) Immunoblot analysis demonstrating that N15C6 cells pre-treated with
vehicle (0.025% DMSO) for 60 min, then treated with 10 pM CXCL12 rapidly accumulate phosphorylated Src (pSrc Tyr 418) as well as the active form
of ADAM10, whereas cells pre-treated with 10 lM of the Src family kinase inhibitor, PP1, neither accumulate pSrc Tyr 418 nor the active form of
ADAM10. (b) Cell lysates prepared from N15C6 cells treated as described in (a) were subjected to immunoprecipitation (IP) using an antibody against
total Src (tSrc). Immunoprecipitated proteins were electrophoresed and immunoblotted against antibodies that recognize phosphotyrosine residues
(pY4G10), pSrcY418, or tSrc. Whole-cell lysates (WCL) from 100 lg untreated N15C6 or 25 lg untreated PC3 cells are included as negative and posi-
tive controls respectively. The immunoblot shown is representative of replicate experiments. (c). Densitometric analysis of replicate immunoblots similar
to that shown (b) demonstrates significant and concomitant accumulation of phosphorylated Src (pSrc Tyr418) (P < 0.05, indicated by *) in N15C6 cells
pre-treated for 60 min with vehicle, then treated with 10 pM CXCL12 for 1 h. Cells pre-treated with PP1 failed to accumulate pSrc in response to
CXCL12. Src activation is indicated as the ratio of pSrc ⁄ tSrc normalized to 1-fold at time 0. Graph plot data have been averaged over replicate experi-
ments as indicated. Error bars reflect deviations from the mean for replicate measures. (d) Assessment and quantification of CXCL12-mediated Src acti-
vation in N15C6 using sandwich ELISA to pSrcY418. One million N15C6 cells grown in serum-free media for 16 h were pre-treated with vehicle
(0.025% DMSO) or vehicle + 5 lM PP1 or +5 lM PP3 for 60 min, followed by stimulation with 10 pM CXCL12 for 60 min. pSrcY418 accumulated to
significantly higher levels (P < 0.05, indicated by *) in response to CXCL12 in vehicle-pre-treated (black bars) and PP3-pre-treated (grey bars), but not
in PP1-pre-treated (striped bars), cells. Graph plot data are averaged over replicate experiments as indicated. Error bars reflect deviations from the mean
for replicate measures. (e). Conditioned media harvested from N15C6 cells (black bars) or PC3 cells (grey bars) plated at 300 000 cells each in triplicate
was evaluated after 16 h incubation in serum-free media followed by pre-treatment with PP1 or vehicle for 60 min, and then with CXCL12 (10 pM for
N15C6 cells, 100 pM for PC3 cells) for an additional 60 min. Sandwich ELISA detected quantified significant (P < 0.05, indicated by *) accumulation
of amphiregulin in the media of N15C6 cells in response to CXCL12, which was significantly (P < 0.05, indicated by #) abrogated by pre-treatment
with the Src family kinase inhibitor, PP1. Neither CXCL12 treatment nor PP1 pre-treatment affected amphiregulin shedding by PC3 cells. The graph
plots data are averaged over replicate experiments as indicated. Error bars reflect deviations from the mean for replicate measures. (f) Conditioned media
harvested from N15C6 cells plated at 300 000 cells each in triplicate was evaluated after 16 h incubation in serum-free media followed by pre-treatment
with vehicle, PP1 or PP3 for 60 min, and then with 10 pM CXCL12 for an additional 60 min. Sandwich ELISA detected significant (P < 0.05, indicated
by *) accumulation of amphiregulin in response to CXCL12 in vehicle- and PP3-, but not in PP1-, pre-treated cells, which was significantly (P < 0.05,
indicated by #) abrogated by pre-treatment with the Src family kinase inhibitor, PP1. Neither CXCL12 treatment nor PP1 pre-treatment affected
amphiregulin shedding by PC3 cells. Graph plot data are averaged over replicate experiments as indicated. Error bars reflect deviations from the mean
for replicate measures.
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10 ng ⁄ml EGF, 10 pM CXCL12 or 100 pM amphiregulin
for 60 min resulted in abundant phosphorylation of the
Y992 residue of EGFR (Fig. 7a). Prolonged treatment of
N15C6 cells with 10 ng ⁄ml EGF, 10 pM CXCL12 or
100 pM amphiregulin over 96 h promoted proliferation of
these cells to levels 1.5- to 2.0-fold higher than achieved
in serum-free media (Fig. 7b). However, proliferation of
N15C6 cells grown for 96 h in serum-free media supple-
mented with 250 nM of the EGFR tyrosine kinase
inhibitor, AG1478, and either 10 ng ⁄ml EGF, 10 pM
CXCL12, or 100 pM amphiregulin was significantly sup-
pressed. These results show that, like EGF- and amphire-
gulin-, CXCL12-mediated cell proliferation required
activation of EGFR. N15C6 cells grown for 96 h in serum-
free media supplemented with 1 lM of the MEK ⁄ERK
inhibitor, U0126, and either EGF or amphiregulin, but not
CXCL12, proliferated to levels significantly above those
observed for population growth in serum-free media
(Fig. 7b). Together, these results show that CXCL12, like
EGF and amphiregulin, must transactivate EGFR ligands
to stimulate cell proliferation. These results also confirm
our earlier findings that CXCL12-stimulated cell prolifera-
tion is MEK ⁄ERK-dependent in N15C6 cells (7).
Discussion
Previous studies have shown that stimulation of the
CXCL12 ⁄CXCR4 axis promotes intracellular signalling
events through the Ras ⁄MEK ⁄ERK and P13K ⁄Akt path-
ways that culminate in diverse cellular responses includ-
ing proliferation (7). However, it has remained unclear
whether the CXCL12 ⁄CXCR4 axis stimulated cell prolif-
eration independently or through transactivation of other
receptors, notably EGFR, that similarly activate these
pathways (14–16). Therefore, the present study was
intended to determine whether the CXCL12 ⁄CXCR4 axis




Figure 7. CXCL12-mediated proliferative responses require EGFR transactivation. (a) N15C6 cells were treated with vehicle (U), 10 ng ⁄ml EGF
(E), 10 pM CXCL12 (C) or 100 pM amphiregulin (A) for 60 min, protein lysates purified, electrophoresed and immunoblotted against antibodies specific
for phospho-EGFR (Y992), total EGFR or tubulin. Robust phosphorylation of EGFR is evident for cells treated with EGF, CXCL12 or amphiregulin.
(b). N15C6 cells were grown for 96 h in SF media supplemented with 10 ng ⁄ml EGF, 10 pM CXCL12 or 100 pM amphiregulin containing vehicle
(0.01% DMSO) or vehicle + 1 lM U0126 or +250 nM AG1478. Proliferation at levels significantly above those achieved in SF media alone (normalized
to 1-fold, not shown) was evident for cells treated with CXCL12, amphiregulin or EGF (*, P < 0.05). Cells co-treated with the EGFR inhibitor,
AG1478, failed to proliferate in response (#, P < 0.05) to EGF, CXCL12 or amphiregulin. However, co-treatment with the MEK inhibitor, U0126, sup-
pressed only the CXCL12-mediated (#, P < 0.05), but not EGF- or amphiregulin-mediated, proliferative response. (c) This schematic drawing demon-
strates potential mechanism(s) for CXCL12-mediated cellular proliferation. Consistent with the data provided in this study, CXCL12 ⁄CXCR4-mediated
Src activation and subsequent ADAM10 (and, possibly, MMP) activation are required for amphiregulin ectodomain shedding. The same mechanisms
may also activate EGFR in a ligand-dependent (amphiregulin shedding) or ligand-independent (Src activation) manner. In either scenario, EGFR trans-
activation is required for CXCL12-mediated proliferation of non-transformed N15C6 prostate epithelial cells. Modified from Prenzel et al.,
Endocr.Relat. Cancer 8: 11–31, 2001. Society for Endocrinology (2009). Reproduced by permission.
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Initial studies examining CXCL12-mediated ectodo-
main shedding of EGFR ligands as a potential mechanism
for CXCL12 ⁄CXCR4-mediated EGFR transactivation
established that prostate stromal fibroblasts, as well as the
majority of non-transformed and transformed prostate epi-
thelial cells tested, constitutively shed the amphiregulin
ectodomain. However, none of these cells shed significant
levels of other EGFR ligands. Ectodomain shedding of
amphiregulin comprises an important regulatory mecha-
nism because it generates functional soluble molecules
through multiple mechanisms, to provide important
proliferative and survival advantages (17,33–39). Auto-
crine secretion of amphiregulin by pre-malignant and
malignant prostate epithelial cells has been reported previ-
ously (40). Torring et al. (41) detected significantly higher
levels of amphiregulin (P < 0.05) in prostate tissue
obtained from patients with BPH treated for 3 months
with finasteride, which inhibits conversion of testosterone
into its active form dihydrotestosterone, compared with
similar tissues from placebo-treated patients. This group
also reported that castrated mice bearing CWR22 human
prostate tumour xenografts demonstrated significantly
higher levels of amphiregulin transcript and secreted pro-
tein compared to non-castrated mice (42). This finding is
consistent with that reported here, as prostate epithelial
cells (N15C6, BPH-1, PC3 and DU145) lacking expres-
sion of the androgen receptor, secreted the highest detect-
able levels of amphiregulin, whereas cells that express the
androgen receptor (LNCaP and 22Rv1) secreted very low
levels of amphiregulin. Although it is unlikely that endog-
enous amphiregulin shedding is strictly related to andro-
gen receptor status in non-transformed nor transformed
prostate epithelial cells, these data do suggest that expres-
sion of EGF-type ligands may provide an autocrine sur-
vival mechanism that enables prostate cells to persist and
multiply in the absence of functional androgen receptor.
Ectodomain shedding of EGF-type ligands, including
amphiregulin, EGF, epiregulin, HB-EGF and TGF-alpha, is
accomplished through cleavage by multiple ADAMs includ-
ing ADAM9, 10, 12, 15, 17 and 19 (18,19,32,43,44). Our
studies also detected active forms of both ADAM10 and
ADAM17 using immunoblot analysis on N15C6 and PC3
cells grown in serum-free media. Moreover, CXCL12-
stimulated amphiregulin shedding was shown to require
metalloprotease activity, as inhibition of this activity using
the pan-metalloprotease inhibitor OPT, the ADAM- and
MMP-inhibitor TAPI-1 or the ADAM10-specific inhibitor
INCB008765, prevented CXCL12-mediated amphiregulin
shedding in N15C6 cells. The observation that TAPI-1 inhib-
ited CXCL12-stimulated amphiregulin secretion was consis-
tent with a general role for ADAMs and ⁄or MMPs in this
process. Twin observations that CXCL12 stimulated
ADAM10 activation over basal levels and that pre-treatment
with ADAM10-specific inhibitor, INCB008765, was suffi-
cient to abrogate both CXCL12-mediated amphiregulin
shedding and proliferation in these cells and indicated that
CXCL12-mediated proliferation in N15C6 cells was
predominantly ADAM10-dependent. This finding is
consistent with that observed for another member of the
CXC-type chemokine family, CXCL8 (IL-8), which has
been shown to mediate amphiregulin shedding through
activation of ADAM10 (19,20). The same study also demon-
strated that knockdown of ADAM10, but not that of
ADAM12 or ADAM17, suppressed CXCL8-induced
amphiregulin shedding and CXCL8-mediated EGFR phos-
phorylation in KATOIII gastric cancer cells (20). However,
the additional finding reported in the present study that
MMP inhibitor, GM6001, also inhibits CXCL12-stimulated
amphiregulin shedding implies that MMPs may play a role
in this process too. Although not definitive and requiring a
more exhaustive evaluation of MMP family members, these
studies provide evidence that amphiregulin shedding may be
modulated by CXC-type chemokines, including CXCL8 and
CXCL12, in human tumour cells, through activation of
ADAM10 and potentially through the further activation
of selected MMPs. These data are consistent with a model of
basal-level autocrine amphiregulin shedding mediated by
constitutively activated ADAM10 and ADAM17 in non-
transformed and transformed prostate epithelial cells. It
should be noted, however, that pre-treatment with OPT did
not diminish basal- nor CXCL12-stimulated ADAM10 acti-
vation nor amphiregulin secretion in transformed PC3 pros-
tate epithelial cells. Taken together, these data suggest that
activation of the metalloprotease activity of ADAM10 is
required for CXCL12-mediated amphiregulin shedding and
proliferation in non-transformed N15C6, but not in trans-
formed PC3, prostate epithelial cells.
As noted above, the major cognate receptor for
CXCL12 is CXCR4, which is G-protein-coupled. Upon
activation, the G-protein heterotrimeric protein associated
with such GPCRs dissociates into the Ga and Gbc hetero-
dimer. Gbc can activate several downstream effectors
including Src family kinases and PKC (12,13) These
kinases can in turn, activate molecules with metallopro-
tease activity, resulting in HB-EGF and amphiregulin
shedding (14,45). In particular, GPCR-coupled mecha-
nisms have been shown to activate both ADAM10 and
ADAM17 (19). The results reported in this study show
that inhibition of CXCL12-mediated Src family kinase
activation prohibited CXCL12-mediated ADAM10 acti-
vation, amphiregulin secretion and cell proliferation. Fur-
thermore, inhibition of Src family kinase activation also
reduced amphiregulin shedding below basal levels in
N15C6 cells. In contrast, inhibition of Src family kinase
activity had no effect on basal amphiregulin shedding in
PC3 cells. These data suggest that both basal and
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CXCL12-mediated amphiregulin shedding are Src family
kinase-dependent in non-transformed N15C6 cells, but
not in transformed, highly aggressive PC3 cells. More-
over, these data suggest that Src family kinase activation
is required for ADAM10 activation as part of a mecha-
nism that promotes CXCL12-mediated amphiregulin
shedding and cell proliferation in N15C6 cells.
The final studies presented here show that EGFR is
phosphorylated equivalently in response to treatment with
EGF, amphiregulin or CXCL12. Moreover, cell prolifera-
tion stimulated by these molecules is equivalently sup-
pressed upon treatment of the cells with the EGFR
inhibitor, AG1478. The observation that inhibition of
signalling along the MEK ⁄ERK pathway reduced cell pro-
liferation significantly for CXCL12-treated cells, but not
for EGF- or amphiregulin-treated cells corresponds to ear-
lier studies from our laboratory demonstrating that
CXCL12-mediated proliferative responses are MEK ⁄
ERK-dependent in N15C6 cells (7). Taken together, these
experiments demonstrate not only that EGFR is transacti-
vated through the CXCL12 ⁄CXCR4 axis but also that this
transactivation is required for CXCL12 ⁄CXCR4-mediated
proliferative response. Moreover, the observation that
Src-dependent ADAM10 activation is required for both
CXCL12-mediated amphiregulin shedding and cell prolif-
eration in N15C6 cells is consistent with ligand-dependent
transactivation of EGFR in these cells (46).
In summary, the data reported in this study and summa-
rized schematically in Fig. 7c (modified with permission
from 14 and 45) identify CXCL12 as a novel inducer of
amphiregulin shedding and show that both basal and
CXCL12-mediated amphiregulin shedding are predomi-
nantly ADAM10- and Src family kinase-dependent in non-
transformed N15C6 cells. Moreover, activation of these
molecules is coupled to CXCL12-mediated ligand-dependent
EGFR transactivation and proliferation of these cells. In con-
trast, amphiregulin shedding is not amplified subsequent to
stimulation with exogenous CXCL12 and is not reduced sub-
sequent to metalloprotease- or Src family kinase inhibition, in
highly aggressive PC3 prostate cancer cells. These findings
indicate that, although autocrine and CXCL12-inducible
secretions of amphiregulin are regulated predominantly
through ADAM- and Src family kinase-mediated mecha-
nisms in non-transformed prostate epithelial cells, these
same mechanisms may be dysfunctional in highly trans-
formed prostate cancer cells. The importance of these
findings is that they show that non-transformed and trans-
formed prostate epithelial cells may utilize different mecha-
nisms to utilize the EGFR axis to promote cell proliferation.
Further work defining the affects of other components of
the cell phenotype, for example, androgen receptor status,
competitive responses to other cytokines and chemokines,
expression profiles of MMP family members, and how
these interact with the CXCL12 ⁄CXCR4 axis to govern
amphiregulin shedding in non-transformed and transformed
prostate epithelial cells, are clearly warranted.
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